Navigation Links
Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
Date:10/20/2008

EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that the Company will host an investor conference call and webcast on Wednesday, October 22 at 4:30 PM Eastern Time to present an analysis of the data from the Isolagen Therapy(TM) Phase III pivotal studies (IT-R-005 and IT-R-006) for the treatment of nasolabial folds, or wrinkles. On August 5, 2008, Isolagen reported positive top-line efficacy and safety results from these two studies, which met all primary endpoints and were highly statistically significant.

The call participants will include Declan Daly, Isolagen's CEO, Dr. Stacy Smith, the Principal Investigator in the Phase III wrinkle studies and Co-Principal Investigator in the Phase II/III acne study, and Dr. Jeanne Novak, Clinical and Regulatory advisor to Isolagen.

A live webcast of the presentation will be accessible on http://www.isolagen.com. To participate in the audio portion of the call, dial 1-800-299-0433 and enter passcode 78803320. An archived replay of the conference call and webcast will be available for 90 days on http://www.isolagen.com or by dialing 1-888-286-8010 and entering passcode 63040312.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Isolagen to Present at the JMP Securities Healthcare Focus Conference
2. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
4. Pharmaxis Investor Conference Call
5. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
6. The Michigan Life Sciences Pipeline Announces The Funding Place(TM) and Other Resources to Connect Investors and Startups
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
8. Halozyme Therapeutics to Host Research Day for Investors and Analysts
9. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
10. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... equipment, to creating professional commercial video content, to analysis of athletic performance. Producing ... events that go by too quickly to process with the naked eye. ...
(Date:9/1/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... Global Investment Conference sponsored by H.C. Wainwright ... St. Regis Hotel in New York, NY ... Chief Executive Officer, will provide an overview of the ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... , ... ... ... ...
... ... ... ... ...
... , ... for Rare Disease Day, hopes to bring more attention to the need for finding more ... ... hopes to draw more attention to the urgent need of finding more treatments for rare ...
Cached Biology Technology:Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO 2Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO 3Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 2Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 5Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 6Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 7Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day 2
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... a molecule on the surface of B cells, a finding ... insidious attack on the immune system, University of Pittsburgh researchers ... , "The research supports a new role for B cells ... important implications for future studies and drug development efforts that ...
... "off" switch packaged in a tiny sphere penetrates deeply ... and drastically reducing the size of tumors, researchers at ... report in the Aug. 15 edition of Clinical Cancer ... cover of the journal, demonstrates a potent delivery system ...
... reported this week reveal that at least some primates can ... for guiding their foraging behavior when searching for ripening fruit. ... skills developed in humans and other primates, is reported by ... of St. Andrews in the June 20th issue of Current ...
Cached Biology News:HIV infection requires an accomplice: B cells with special protein direct HIV to T cells 2Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial 2Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial 3Primates take weather into account when searching for fruits 2
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Request Info...
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Biology Products: